Sunshine Biopharma Inc. insider trading

Every open-market purchase and sale by Sunshine Biopharma Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Sunshine Biopharma Inc.’s insiders pay?

From September 7, 2012 to March 5, 2024, 2 insiders reported 5 open-market purchases and 1 sale not made under a pre-set plan in Sunshine Biopharma Inc.

Sunshine Biopharma Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Slilaty Steve N.	Chief Executive Officer	3	—	—	1	—	March 5, 2024
Sebaaly Camille	CFO/Secretary	2	—	—	0	—	December 2, 2022

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Sunshine Biopharma Inc. · Funds · Politicians